Brief Definitive Report

Transmission Blocking Immunity in Plasmodium vivax Malaria: Antibodies Raised against a Peptide Block Parasite Development in the Mosquito Vector

By Valerie A. Snewin,* Sunil Premawansa, Gamini M. G. Kapilananda, Lalinda Ratnayaka, Preethi V. Udagama, Denise M. Mattei, Elizabeth Khouri, Giuseppe Del Giudice, J. S. M. Peiris, Kamini N. Mendis, and Peter H. David*

From the *Unité d’Immunoparasitologie, and the *Unité de Parasitologie Experimentale, Centre National de la Recherche Scientifique URA361, Institut Pasteur, 75724 Paris, France; the $Department of Zoology, Faculty of Science, University of Colombo, Colombo 3, Sri Lanka; the ||Malaria Research Unit, Department of Parasitology, Faculty of Medicine, University of Colombo, Colombo 8, Sri Lanka; and the $2 of Biochemistry, University of Lausanne, Chemin des Boveresses, CH-1066 Epalinges-sur-Lausanne, Switzerland

Summary

One approach towards the development of a vaccine against malaria is to immunize against the parasite sexual stages that mediate transmission of the parasite from man to mosquito. Antibodies against these stages, ingested with the blood meal, inhibit the parasite development in the mosquito vector, constituting “transmission blocking immunity.” Most epitopes involved in transmission-blocking immunity depend on the tertiary conformational structure of surface antigens. However, one of the transmission-blocking monoclonal antibodies we have raised against Plasmodium vivax reacts with a linear epitope on both asexual stages and gametes. This monoclonal antibody (A12) is capable of totally blocking development of the parasite in the mosquito host when tested in membrane feeding assays with gametocytes from P. vivax-infected patients. Immune screening of a P. vivax Xgt11 genomic expression library with A12 led to the isolation of a clone to which was mapped the six-amino acid epitope recognized by A12. Antisera raised in mice against a 12-mer synthetic peptide containing this epitope coupled to bovine serum albumin not only had high titers of antipeptide antibodies as measured by enzyme-linked immunosorbent assay, but in addition recognized the same 24- and 57-kD parasite components as A12 on Western blots and reacted with the parasite by immunofluorescence. When tested in membrane feeding assays, these antibodies have significant suppressive effects on parasite development in the mosquito.

Transmission-blocking vaccines against malaria are based on immunity mediated by antibodies against parasite sexual stages. These antibodies block the development of the malaria parasite in the mosquito host (reviewed in reference 1). Such vaccines, while not protecting the vaccinated individual, would prevent subsequent transmission of the parasite. They would thus be effective at a community level, both by reducing transmission and also by preventing the spread of parasites rendered resistant through drug or immune pressure exerted on asexual blood stages. It has been demonstrated that Plasmodium vivax patients can readily develop antibodies against parasite sexual stages (2). This leads to natural transmission-blocking immunity that significantly lowers the incidence of infection (3). The ability of antibodies to block parasite transmission or suppress infectivity is tested by membrane feeding, a biological assay that directly reflects the phenomenon arising in naturally infected patients (described in reference 4).

mAbs with transmission-blocking activity have allowed the definition of specific targets of transmission-blocking immunity on the surface of P. falciparum sexual stages (5, 6). Several genes coding for these target antigens have now been cloned (Pfs25, Pfs48/45, and Pfs230). Such cloning was achieved through screening libraries with oligonucleotide probes, the sequence of which was derived from microsequencing of purified parasite antigens, not through immune screening of expression DNA libraries. This is because transmission-blocking antibodies predominantly recognize conformationally dependent epitopes that are not usually suitably reproduced in Escherichia coli (1).
Because of the lack of significant cross-reactive immunity and of DNA cross-hybridization between *P. falciparum* and *P. vivax*, the characterization of species-specific molecules which are targets of transmission-blocking immunity, is required for the development of an effective vivax transmission-blocking vaccine. We have characterized such molecules through isolation of several transmission-blocking mAbs (described in reference 10). All but one of these antibodies recognize epitopes that depend on tertiary structures of the parasite surface antigens and are thus not good candidates for screening reference 10). All but one of these antibodies recognize epitopes that depend on tertiary structures of the parasite surface antigens and are thus not good candidates for screening expression libraries constructed in *E. coli*. However, the difficulties inherent in obtaining large quantities of *P. vivax* parasites (this parasite cannot be maintained in long-term cultures), limit the use of protein purification and micro-sequencing as the basis for cloning relevant genes.

Here we describe the use of a *P. vivax* transmission-blocking mAb (A12), which recognizes a linear epitope, to identify a clone upon immune-screening of an Agt11 *P. vivax* expression library. The six amino acids which encompass the linear epitope recognized by this mAb have been mapped within the translated amino acid sequence of this clone and the ability of a corresponding peptide assessed for its ability to elicit transmission-blocking or infectivity-suppressing antibodies. Antibodies raised in mice against a synthetic peptide comprising this epitope have the capacity to significantly suppress infectivity of the parasite in the mosquito, as measured by membrane feeding assays. Both the monoclonal and monospecific polyclonal antibodies recognize the same parasite components on Western blots and react with sexual as well as asexual stage parasites by immunofluorescence.

**Materials and Methods**

**Parasite Material.** *P. vivax* gametocytes for membrane feeding experiments and Western blots were obtained, under informed consent, from patients admitted to the Colombo General Hospital in Sri Lanka. Female gametocytes were prepared as described in Munesinghe et al. (4). Parasites used for all nucleic acid studies were obtained from *Saimiri sciureus* monkeys (Guyana phenotype) infected with the *P. vivax* Belem isolate. Purified parasites were prepared and extracted for DNA as detailed in (11), for RNA by the method of Chomczynski and Sacchi (12) or were resuspended in nonreducing SDS-PAGE sample buffer for Western blots (13). Immunofluorescence slides were prepared from infected human or monkey blood. Immunofluorescence on air-dried slides was performed as described (13) with the modification of 5% FCS added to incubation solutions. mAb The mAb A12 was raised against the surface of *P. vivax* asexual stage parasites. It has previously been described (13).

**Library Production and Screening.** The *P. vivax* genomic DNA library, has been previously described (11). Both the Agt11 and pGex libraries were constructed through DNaseI digestion of DNA in the presence of manganese, based on the method of Mathei et al. (14). Antibody screening was carried out on 10^9 phage from the unamplified Agt11 library or 5,000 pGex colonies, on appropriate filters containing 10 mM IPTG (isopropyl-β-D-thiogalactoside), using the A12 mAb ascitic fluid and iodinated protein A (Amersham France SA, Les Ulis, France). Sequencing was carried out according to dideoxy technology using the Sequenase kit (United States Biochemical Corp., Cleveland, OH) as recommended by the manufacturers. Other DNA techniques were carried out based on standard protocols of (15).

**SDS-PAGE and Western Blot Analysis.** Approximately 2 × 10^7 parasites were loaded onto 10% mini SDS-PAGE gels and migrated under reduced conditions, using prestained molecular weight markers (Bio-Rad Laboratories, Hercules, CA). Western blots were carried out in a Bio-Rad Mini Trans-Blot Cell. Antibodies were diluted appropriately and reacted with alkaline phosphatase-conjugated anti-mouse second antibody (diluted 1:7,500) and appropriate substrates (Promega, Madison, WI).

**Peptide Synthesis.** A set of 46 peptides was purchased from Cambridge Research Biochemicals Ltd. (Northwich, Cheshire, UK). Each peptide consisted of 12 residues overlapping by one amino acid, bound to a solid polyethylene pin support in the same layout as a standard ELISA plate. The mAb culture supernatant was reacted against these pins and revealed using an antimouse (Promega) conjugate diluted 1:2,000. This was carried out according to the manufacturer's recommendations, except that the antibody and conjugate were diluted in 1% vol/vol FCS, 0.1% vol/vol Tween-20, 0.1% wt/vol BSA in 0.01 M PBS, pH 7.2, instead of the solution given in the protocol. Free synthetic peptides (>95% pure by HPLC) were produced at the Pasteur Institute Organic Chemistry Unit, using solid-phase technology containing a cysteine residue for conjugation to activated BSA using the Immject activated SuperCarrier system (Pierce, Rockford, IL).

**Immunization Protocols.** A set of 46 peptides was purchased from Cambridge Research Biochemicals Ltd. (Northwich, Cheshire, UK). Each peptide consisted of 12 residues overlapping by one amino acid, bound to a solid polyethylene pin support in the same layout as a standard ELISA plate. The mAb culture supernatant was reacted against these pins and revealed using an antimouse (Promega) conjugate diluted 1:2,000. This was carried out according to the manufacturer's recommendations, except that the antibody and conjugate were diluted in 1% vol/vol FCS, 0.1% vol/vol Tween-20, 0.1% wt/vol BSA in 0.01 M PBS, pH 7.2, instead of the solution given in the protocol. Free synthetic peptides (>95% pure by HPLC) were produced at the Pasteur Institute Organic Chemistry Unit, using solid-phase technology containing a cysteine residue for conjugation to activated BSA using the Immject activated SuperCarrier system (Pierce, Rockford, IL).

**Immunization Protocols.** A set of 46 peptides was purchased from Cambridge Research Biochemicals Ltd. (Northwich, Cheshire, UK). Each peptide consisted of 12 residues overlapping by one amino acid, bound to a solid polyethylene pin support in the same layout as a standard ELISA plate. The mAb culture supernatant was reacted against these pins and revealed using an antimouse (Promega) conjugate diluted 1:2,000. This was carried out according to the manufacturer's recommendations, except that the antibody and conjugate were diluted in 1% vol/vol FCS, 0.1% vol/vol Tween-20, 0.1% wt/vol BSA in 0.01 M PBS, pH 7.2, instead of the solution given in the protocol. Free synthetic peptides (>95% pure by HPLC) were produced at the Pasteur Institute Organic Chemistry Unit, using solid-phase technology containing a cysteine residue for conjugation to activated BSA using the Immject activated SuperCarrier system (Pierce, Rockford, IL).

**Membrane Feeding Assays.** Each assay was carried out using gametocyte-infected blood from a *P. vivax* patient. For each assay, 150 μl of infected erythrocytes was resuspended in 75 μl of mouse antiparasite sera and 75 μl of normal AB human sera. This was fed to 50 female *Anopheles tesselatus* mosquitoes in a membrane-feeding apparatus prewarmed to 37°C. Nonfed mosquitoes were subsequently removed and the fed mosquitoes maintained at 26°C ± 2°C. The number of oocysts developing in the mid gut was examined microscopically after 7 d after boosting.

**ELISA.** Antibody titers were tested for individual mice after every immunization with the peptide conjugates, by ELISA either employing free peptide as antigen or appropriate peptide coupled to KLH as carrier. 96-well plates (Nunc, Roskilde, Denmark) were routinely coated at 0.5 μg/ml quenched in PBS-Tween-gelatin and revealed using horseradish peroxidase anti-mouse conjugate (Promega) diluted 1:2,000. Plates were read at 405 nm (490 value subtracted automatically) via a plate reader (Molecular Devices; Palo Alto, CA) and corresponding software.

**Results and Discussion**

Upon the immune-screening of a Agt11 *P. vivax* genomic expression library with the A12 mAb, a clone was identified which contained a 1.5-kb insert. Upon induction, a recombinant fusion protein was produced in *E. coli* corresponding to 132 kD on reduced SDS-PAGE gels, indicating a parasite component of ~16 kD. The translated amino acid sequence bore no significant homology to sequences in the GenBank.

358 Vivax Malaria Transmission Blocking Abs against A Peptide
database (release 82), using a BLAST search (16) (data not shown).

To identify the linear epitope of this \textit{P. vivax} transmission-blocking mAb, a sublibrary corresponding to the Agt11 clone was constructed in a bacterial expression system. DNaseI-generated fragments were prepared according to previous protocols (14), EcoRI linkered and ligated into the pGex expression vector (17). These clones were then screened with the A12 mAb. Out of 25 putative clones, 23 constructs expressing the A12 epitope were confirmed by Western blot analysis. Corresponding DNA sequences were obtained using plasmid-specific oligonucleotide primers, and ranged between 96 and 402 bp, all clones overlapping with 100 bp at the 3' end of the coding sequence.

One of these constructs (clone 21, Fig. 1) was used to immunize BALB/c mice and the sera obtained reacted on Western blots of either \textit{P. vivax} asexual stages or gametocytes extracted under reducing conditions. The antibodies produced upon immunization with the fusion protein identified the same pattern of bands as the original mAb A12, corresponding to a more intense 24-kD band plus an additional band of 57 kD, as estimated from reduced SDS-PAGE gels, (Fig. 2 A, panels 1 and 2).

From an analysis of the DNA sequence encoding the open reading frame in phase with the Glutathione S-Transferase (GST) fusion protein of the smallest of the pGex clones, (clone 21, Fig. 1 B), the A12 epitope was mapped to a 32-amino acid region, corresponding to the COOH-terminal region of the predicted protein. To further delimit the A12 epitope sequence, synthetic peptide pin technology was employed. 46 overlapping peptides corresponding to this region were constructed and incubated with the A12 mAb. This mapping revealed the epitope of the monoclonal to consist of the six amino acids: TWEVLH (Fig. 1 A). A 12-mer peptide (Ep: CPLPTWEVLHDGS), corresponding to the predicted amino acid sequence containing this epitope was synthesized. As a control, a peptide representing the "Universal T cell epitope" from the \textit{P. falciparum} CS protein, (Tu: EKKIAK-MEKASSVFNVVC) (18) was employed. Peptides were coupled to a BSA carrier before immunization of BALB/c mice using aluminium hydroxide (Alum) as adjuvant, the only adjuvant currently accepted for human use.

Upon two immunizations with the Ep peptide, antibodies were produced which reacted with the same pattern on parasite Western blots as the A12 mAb (Fig. 2 A, lanes 1 and 3). The presence of a higher molecular weight band (~65 kD) on Western blots when both the epitope peptide and control sera are reacted with the gamete antigen is probably due to the presence of human serum albumin contaminating this antigen preparation. The fact that the profiles on Western blotting are otherwise identical indicates that the target molecule recognized by these antibodies may indeed be present in both asexual as well as sexual blood stage parasites, unlike other targets of transmission-blocking immunity described to date (1). A12 and antipeptide sera demonstrated reactivity with the parasite, both with asexual parasites and with female gametes on immunofluorescence. There was no reactivity with the control peptide sera at the dilutions tested (1/20–1/500).

Each mouse serum sample was tested for reactivity individually by ELISA then pooled for use in transmission-blocking assays. Individual mice ELISA titers are not shown but were highly uniform throughout each group of mice. The antipeptide titers for the pooled sera used in membrane-feeding analysis are shown in Fig. 3. Antibody titers specific to both peptides reached high levels even after the second immunization.

![Figure 1.](image-url)
Figure 3. ELISA titers of pooled sera used in membrane-feeding assays from the third and fifth immunizations. The uncoupled peptide at 3 μg/ml was used as antigen. Plates were coated and serum incubated overnight at 4°C before second antibody incubation at 37°C for 3 h. Ep indicates the A12 epitope sera and Tu, the control sera. (□) Ep third immunization; (△) Ep fifth immunization bled after 7 d; (■) Ep fifth immunization bled after 22 d; and (▲) Ep fifth immunization bled 44 d after immunization. All the Tu sera give very low absorption (<0.20 OD₄₉₀-₅₄₀ U) when tested against the Ep peptide. The reciprocal of the dilution is shown on the x abscissa (Dilution).

Figure 2. (A) Western blots of reduced P. vivax antigen from either asexual (A) or gamete (G) preparations, reacted with the A12 mAb in lane 1, the pGex clone 21 recombinant sera (third immunization) in lane 2, and the epitope peptide antibodies in lane 3, consisting of the antibody pool employed in membrane feeding, fifth immunization. Control antisera raised against the control peptide and pGex GST fusion protein alone are illustrated in lanes 4 and 5, respectively. All sera were employed diluted 1/400. (B) Immunofluorescence of air-dried parasite antigen from asexual stages and gamete preparation reacted with the epitope peptide antibodies. Sera was diluted 1/250; the control peptide antisera gave no fluorescence at this dilution and is not shown.

three different time points after the fifth injection were tested against the same parasite isolate (experiments 8–10) and significant infectivity suppressive effects were shown even 6 wk after immunization. Despite the variability of these results, they represent a significant reduction in infectivity. In 5 out of the 10 experiments, the immune sera reduced the number of mosquitoes infected to <50% of that in controls and in every case there is a reduction in the number of mosquitoes infected for the epitope peptide compared to the control (after correcting for the numbers of mosquitoes counted).

The variability in the infectivity suppressive effects demonstrated in these experiments may be explained by the fact that each experiment was performed using gametocyte-infected blood from a different infected donor. They are therefore likely to differ in the gametocyte count, the ratio of male and female gametocytes, and possibly in recognition of the epitope, all of which are known to influence the impact of an infectivity suppressing antibody. The inability to use a standard parasite isolate for testing is an invariable technical difficulty encountered with P. vivax due to the lack of continuous in vitro culture.

It has recently been proposed that control measures aimed at decreasing transmission rates of malaria parasites may be more effective than previously predicted (19). Moreover, the observation that a reduction of the levels of transmission through the use of insecticide treated bed nets could significantly reduce morbidity (20, 21) indicates that transmission-blocking immunity, even if incomplete, could have an impact on disease as well as reduce the spread of drug- or vaccine-resistant parasites. We have thus demonstrated that antibodies which suppress infectivity can be raised in mice by immunization with a small peptide. This raises the hope that at least in the case of some target antigens of transmission-blocking immunity, eukaryotic expression of large recom-
Table 1. Membrane Feeding Results Demonstrating the Effect of the Anti-A12 Epitope Peptide Sera on P. vivax Infectivity to Mosquitoes

| Expt. No. | MR No. | Mean oocyst per gut Anti-sera raised against: | Percent infectivity Mann-Whitney U test |
|-----------|--------|---------------------------------------------|---------------------------------------|
|           |        | Epitope peptide                             | Control peptide                       |
|           |        |                                             | p value at 95%                         |
| 1        | 3324   | 1.6 (8/20)                                  | 27.3 (12/20)                           |
| 2        | 3331   | 12.0 (8/20)                                 | 53.1 (19/22)                           |
| 3        | 3334   | 16.3 (11/21)                                 | 88.9 (11/13)                           |
| 4        | 3339   | 20.8 (8/18)                                 | 62.5 (9/17)                            |
| 5        | 3340   | 23.5 (10/17)                                 | 94.4 (20/21)                           |
| 6        | 3393   | 3.3 (10/17)                                 | 31.3 (11/20)                           |
| 7        | 3396   | 28.8 (7/20)                                 | 94.5 (13/21)                           |
| 8        | 3398   | 14.6 (5/22)                                 | 56.8 (14/22)                           |
| 9        | 3398   | 11.4 (5/21)                                 | 51.3 (13/20)                           |
| 10       | 3398   | 18.5 (6/20)                                 | 57.9 (14/20)                           |

The percent infectivity of the A12 epitope peptide (Ep) compared to the control (Tu) is shown for each of the 10 feedings (Expt. No.) where p values correspond to a 95% confidence level for a Mann-Whitney U test, applied to random samples. The MR No. is the parasite isolate number used in each feeding. The number of mosquitoes infected/number mosquitoes dissected is shown in parentheses for the Ep and Tu peptide serum. The mean oocyst per gut is shown after feeding mosquitoes in the presence of antibodies raised against either the epitope or control peptide.

*p <0.05 is significant.

1 Sera from the third immunization.
2 Sera from the fifth injection taken 7 d after immunization.
3 Sera from the fifth injection taken 22 d after immunization.
4 Sera from the fifth injection taken 44 d after immunization.

Immunization of mice with the A12 epitope peptide led to antibodies that completely blocked parasite development in a number of mosquitoes, and significantly lowered oocyst burdens using experimental infections of laboratory mosquitoes. Similar results, if they were to be obtained in natural infections, where oocyst numbers are usually lower than those obtained here, could have significant effects on P. vivax incidence and morbidity.

We thank Professor Michel Rabinovitch for support; Vladimir Zilberfab, Genéviève Milon, and Antonella Pessi for invaluable help; Anura Jayasinghe and Yamuna Raff for technical assistance; and Odile Mercereau-Puijalon for critically reviewing the manuscript. We also thank the physicians and staff of the medical wards of the General Hospital, Colombo, for their cooperation.

This work was supported by the United Nations Development Programme/World Bank/World Health Organisation Special Programme for Research and Training in Tropical Disease (TDR), by the Rockefeller Foundation, the EEC programme for Life Science and Technologies in Developing Countries (STD3), the Centre National de la Recherche Scientifique, the Pasteur Institute, and the "Ministère de la Recherche et de l'Enseignement Supérieur".

Address correspondence to Dr. Valerie A. Snewin, Unité d'Immunoparasitologie, Institut Pasteur, 25-28 Rue du Dr. Roux, 75724 Paris, cedex 15, France.

Received for publication 20 July 1994 and in revised form 27 September 1994.

References

1. Kaslow, D.C. 1994. Progress towards a transmission-blocking vaccine. In Molecular Immunological Considerations in Malaria Vaccine Development. M.F. Good and A.J. Saul, editors. CRC Press, London. 209–244.
2. Mendis, K.N., Y.D. Munasinghe, Y.N.Y. De Silva, I. Keragalla, and R. Carter. 1987. Malaria transmission-blocking immunity induced by natural infections of *Plasmodium vivax* in humans. *Infect. Immun.* 55:369–372.

3. De Zoysa, A.P.K., P.R.J. Herath, T.A. Abhayawardana, U.K.G.K. Padmalal, and K.N. Mendis. 1988. Modulation of human malaria transmission by anti-gamete transmission blocking immunity. *Trans. R. Soc. Trop. Med. Hyg.* 82:548–553.

4. Munasinghe, Y.D., K.N. Mendis, and R. Carter. 1986. Anti-gamete antibodies block transmission of human vivax malaria to mosquitoes. *Parasite Immunol.* (Oxf). 8:231–238.

5. Graves, P.M., R. Carter, T.R. Burkot, J. Rener, D.C. Kaushal, and J.L. Williams. 1985. Effects of transmission-blocking monoclonal antibodies on different isolates of *Plasmodium falciparum*. *Infect. Immun.* 48:611–616.

6. Foo, A., R. Carter, C. Lambros, P. Graves, I. Quakyi, G.A.T. Targett, T. Ponnudurai, and G.E. Lewis, Jr. 1991. Conserved and variant epitopes of target antigens of transmission-blocking antibodies among isolates of *Plasmodium falciparum* from Malaysia. *Am. J. Trop. Med. Hyg.* 44:623–631.

7. Kaslow, D.C., I.A. Quakyi, C. Syin, M.G. Raum, D.B. Keister, J.E. Coligan, T.F. McCutchan, and L.H. Miller. 1988. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. *Nature* (Lond.). 333:74–76.

8. Kocken, C.H.M., J. Jansen, A.M. Kaan, P.J.A. Beckers, T. Ponnudurai, D.C. Kaslow, R.N.H. Konings, and J.G.G. Schoenmakers. 1993. Cloning and expression of the gene for the transmission-blocking target antigen Pf48/45 of *Plasmodium falciparum*. *Mol. Biochem. Parasitol.* 61:59–68.

9. Williamson, K.C., M.D. Criscio, and D.C. Kaslow. 1993. Cloning and expression of the gene for *Plasmodium falciparum* transmission-blocking target antigen, Pf230. *Mol. Biochem. Parasitol.* 58:355–358.

10. Premawansa, S., M.J.S. Peiris, K.L.R. Lakshman Perera, G. Ariyaratne, R. Carter, and K.N. Mendis. 1990. Target antigens of transmission blocking immunity of *Plasmodium vivax* malaria. *J. Immunol.* 144:436–438.

11. Del Portillo, H., J. Gysin, D.M. Mattei, E. Khouri, P.V. Udagama, K.N. Mendis, and P.H. David. 1988. *Plasmodium vivax*: cloning and expression of a major blood-stage surface antigen. *Exp. Parasitol.* 67:346–353.

12. Chomczynski, P., and N. Sacchi. 1987. Single-step of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal. Biochem.* 162:156–159.

13. Udagama, P.V., P.H. David, J.S.M. Peiris, Y.G. Ariyaratne, K.L.R. Perera, and K.N. Mendis. 1987. Demonstration of antigenic polymorphism in *Plasmodium vivax* malaria with a panel of 30 monoclonal antibodies. *Infect. Immun.* 55:2604–2611.

14. Mattei, D., G. Langsley, C. Braun-Breton, M. Guillotte, J.F. Dubremetz, and O. Mercereau-Puijalon. 1988. The S-antigen of *Plasmodium falciparum* Palo Alto represents a new S-antigen serotype. *Mol. Biochem. Parasitol.* 27:171–180.

15. Sambrook, J., E.F. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A Laboratory Manual. 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.

16. Altschul, S.F., W. Gish, W. Miller, E.W. Myers, and D.J. Lipman. 1990. Basic local alignment search tool. *J. Mol. Biol.* 215:403–410.

17. Smith, D.B., and K.S. Johnson. 1988. Singlestep purification of polypeptides expressed in *Escherichia coli* as fusions with glutathione S-transferase. *Gene.* 67:31–40.

18. Sinigaglia, F., M. Guttinger, J. Kilgus, D.M. Doran, H. Matile, H. Ertlinger, A. Trzeciak, D. Gillesen, and J.R.L. Pink. 1988. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. *Nature* (Lond.). 336:22–29.

19. Gupta, S., K. Trenholme, R.M. Anderson, and K.P. Day. 1994. Antigenic diversity and the transmission dynamics of *Plasmodium falciparum*. *Science* (Wash. DC). 263:961–963.

20. Alonso P.L., S.W. Lindsay, J.R.M. Armstrong, M. Conteh, A.G. Hill, P.H. David, G. Fegan, A. De Francisco, A.J. Hall, F.C. Shenton, K. Cham, and B.M. Greenwood. 1991. The effect of insecticide-treated bed nets on mortality of Gambian children. *Lancet.* 337:1499–1502.

21. Greenwood, B.M., and J.R. Baker, editors. 1993. A malaria control trial using insecticide-treated bed nets and targeted chemoprophylaxis in a rural area of the Gambia, West Africa. *Trans. R. Soc. Trop. Med. Hygiene.* 87 (Suppl. 2). 1–60.